SnapShot: Ca2+-Calcineurin-NFATSignaling
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Ca2+-calcineurin-NFAT signaling transmits signals to the nucleus from a wide variety of receptors and is required for developmental events as diverse as axon outgrowth, cardiac morphogenesis, lung morphogenesis, neural crest diversification, epithelial stem cell maintenance, and immune responses. The pathway appears to be particularly dedicated to vertebrate-specific morphogenic events, perhaps reflecting its first evolutionary appearance in vertebrates. Calcineurin-NFAT signaling is the target of the drugs cyclosporin A and FK506 and several viral immune modulators. In addition, its malfunction is implicated in Down’s syndrome, diabetes, and cardiac hypertrophy. Receptors that induce the entry of Ca2+ into the cell resulting in the activation of calcineurin phosphatase are shown in the lower left. Ca2+ binds to the regulatory subunit of calcineurin as well as to calmodulin to activate the phosphatase activity of calcineurin (Stemmer and Klee, 1994). The immunosuppressive drugs FK506 and cyclosporin A inhibit calcineurin by binding first to the abundant intracellular proteins, FKBP and cyclophilin, respectively. These protein complexes then bind to calcineurin, preventing substrate access (Liu et al., 1991). The specificity of these calcineurin inhibitors is due to the large composite surface arising from FKBP bound to FK506 (see inset structure) (Griffith et al., 1995) or cyclosporin A bound to cyclophilin. FK506 and cyclosporin A are highly specific probes of the NFAT signaling pathway in tissues where the concentration of calcineurin is less than the concentration of FKBP or cyclophilin (Graef et al., 2001). Calcineurin removes several phosphate residues from the N terminus of NFATc proteins, the Ca2+-calcineurin-sensitive subunits of NFAT transcription complexes. Removal of the phosphates exposes nuclear localization sequences in NFATc proteins leading to their rapid entry into the nucleus (Beals et al., 1997a). Once in the nucleus, the NFATc proteins assemble on DNA with partner proteins generically termed NFATn (lower right) that are often the endpoints of other signaling pathways (Crabtree and Olson, 2002). In most cases, NFAT-dependent transcription requires that the Ca2+ signaling be coincident with MAP kinase signaling, providing a mechanism for signal integration and coincidence detection. The targets of NFAT signaling (panel, upper right) are largely cytokines, growth factors and their receptors, proteins involved in cell-cell interactions, as well as many microRNAs. Of particular importance are positive feedback loops initiated by direct binding of NFATc1 and NFATc4 to their promoters as well as the regulation of Ca2+ channels, such as the IP3 receptor, responsible for the release of intracellular Ca2+ stores (Genazzani et al., 1999). This positive feedback loop appears to be important in committing cells to specific fates. A negative feedback loop mediated by the NFAT-dependent activation of RCAN (DSCR1) gene expression appears to constrain the pathway (Arron et al., 2006). NFATc proteins are actively removed from the nucleus by first priming with Dyrk1a or protein kinase A (PKA) followed by phosphorylation by GSK3 (Arron et al., 2006; Beals et al., 1997b; Gwack et al., 2006). The inhibition of GSK3 by AKT and PI3 kinase (PI3K) signaling increases the level of NFATc proteins in the nucleus and hence provides a second means of coincidence detection and signal integration. Many of the phenotypes of Down’s syndrome are thought to be due to the duplication of the DSCR and Dyrk1a genes on chromosome 21. Increased gene dosage both reduces NFATc import into the nucleus and also facilitates export leading to a reduction in NFATc function and compromised positive feedback (Arron et al., 2006).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes
Liu, J., Farmer, J. D., Lane, W. S., Friedman, J., Weissman, I., & Schreiber, S. L. (1991) · Cell · doi:10.1016/0092-8674(91)90124-h · Cited by 4,116 · cited 1×
“These protein complexes then bind to calcineurin, preventing substrate access (Liu et al., 1991).”
Self-citationCrabtree, G. R., & Olson, E. N. (2002) · Cell · doi:10.1016/s0092-8674(02)00699-2 · Cited by 1,323
Self-citationNFAT dysregulation by increased dosage of DSCR1 and DYRK1A on chromosome 21
Arron, J. R., Winslow, M. M., Polleri, A., Chang, C.-P., Wu, H., Gao, X., Neilson, J. R., Chen, L., Heit, J. J., Kim, S. K., et al. (2006) · Nature · doi:10.1038/nature04678 · Cited by 698
Self-citation
Cited by
Schreiber, S. L. (2021) · Cell · doi:10.1016/j.cell.2020.12.020 · Cited by 598
Self-citationNFAT, immunity and cancer: a transcription factor comes of age
Müller, M. R., & Rao, A. (2010) · Nature Reviews Immunology · doi:10.1038/nri2818 · Cited by 597
A Synthetic Optogenetic Transcription Device Enhances Blood-Glucose Homeostasis in Mice
Ye, H., Baba, M. D.-E., Peng, R.-W., & Fussenegger, M. (2011) · Science · doi:10.1126/science.1203535 · Cited by 467
Deciphering the astrocyte reaction in Alzheimer's disease
Perez-Nievas, B. G., & Serrano-Pozo, A. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00114 · Cited by 282
“Calcium/Calcineurin/NFAT Pathway The calcium/CN/NFAT pathway links cytosolic calcium levels to gene expression (Crabtree and Schreiber, 2009).”
BackgroundMechanisms Modulating Skeletal Muscle Phenotype
Blaauw, B., Schiaffino, S., & Reggiani, C. (2013) · Comprehensive Physiology · doi:10.1002/cphy.c130009 · Cited by 256
Molecular glues and bifunctional compounds: Therapeutic modalities based on induced proximity
Schreiber, S. L. (2024) · Cell Chemical Biology · doi:10.1016/j.chembiol.2024.05.004 · Cited by 112
Self-citationLy, N., & Cyert, M. S. (2017) · Molecular Biology of the Cell · doi:10.1091/mbc.e16-06-0432 · Cited by 14
“In mammals, CN is best known as the target of immunosuppressant drugs cyclosporin A and FK506, which inhibit CN-mediated dephosphorylation of NFAT transcription factors to block T-cell activation (Crabtree and Schreiber, 2009).”
Background
Metadata
- Authors
- Crabtree, G. R., & Schreiber, S. L.
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2009-07
- Volume
- 138
- Issue
- 1
- Pages
- 210-210.e1
- ISSN
- 0092-8674 (ISSN-L)
- OpenAlex
- W2058088852
- Cited by
- 105
- References
- 3
- FWCI
- 2.28
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.